Biogen's $5.6 Billion Buy of Apls Stock: What It Means for Rare Disease Growth

• Biogen agreed to buy Apellis for $5.6 billion to expand its rare disease and nephrology offerings
• The deal gives Biogen access to two FDA-approved drugs: EMPAVELI and SYFOVRE, which generated $689 million in 2025 revenue
• Apls stock jumped 140% in pre-market trading after the deal was announced
• The acquisition is expected to be accretive to Biogen's non-GAAP diluted EPS starting in 2027
• Apellis shareholders may receive additional payments based on SYFOVRE's future sales milestones

Biogen's $5.6 billion acquisition of Apellis Pharmaceuticals is reshaping the rare disease landscape. The deal, announced March 31, 2026, adds two FDA-approved drugs to Biogen's portfolio: EMPAVELI for immune-mediated kidney diseases and paroxysmal nocturnal hemoglobinuria (PNH), and SYFOVRE for geographic atrophy due to age-related macular degeneration. These products generated $689 million in combined revenue in 2025, with growth projections of mid-to-high teens annually through 2028. For investors, the deal marks a strategic pivot by Biogen as it seeks to offset declining revenue from its multiple sclerosis (MS) drugs and slow adoption of its Alzheimer's treatment.

Why Is Apls Stock Surging After the Biogen Deal?

Apellis stock (APLS) surged 140% in pre-market trading after the acquisition announcement. The deal offers $41 per share in cash, more than double the closing price. Shareholders may also receive two additional $2-per-share payments if SYFOVRE achieves certain sales milestones. This premium reflects Biogen's belief in the growth potential of Apellis' rare disease and immunology portfolio. For retail investors, the stock's sharp rise signals strong market confidence in the deal's value. However, the stock's volatility remains a risk, especially if Syfovre's sales fall short of expectations.

How Does This Acquisition Strengthen Biogen's Growth Strategy?

Biogen's acquisition is part of a broader strategy to expand its presence in nephrology and rare diseases. The company is leveraging Apellis' commercial infrastructure to support the potential launch of its experimental drug, felzartamab. The deal is expected to be increasingly accretive to non-GAAP diluted earnings per share (EPS) starting in 2027, significantly boosting Biogen's long-term growth profile. For investors, the move demonstrates Biogen's commitment to diversifying its revenue base as it navigates the challenges of MS drug competition and Alzheimer's treatment skepticism. The company also plans to de-lever by the end of 2027, mitigating financial risk.

What Investors Should Watch in the Months Ahead

The success of Biogen's strategy will depend on several factors. First, the integration of Apellis' sales team and product portfolio must proceed smoothly. Second, regulatory and market acceptance of Syfovre will play a crucial role in realizing the expected revenue growth. Lastly, Biogen's ability to maintain its financial flexibility while funding the acquisition will be key. For now, the deal represents a significant step forward in Biogen's rare disease ambitions and could reshape the competitive landscape in nephrology and immunology.